Study on the Clinical Efficacy of Teclistamab

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Multiple MyelomaHematologic Diseases
Interventions
DRUG

Teclistamab

Intervention is part of standard clinical care, as Tecvayli/Teclistamab is reimbursed for this group of patients.

Trial Locations (17)

1070

RECRUITING

Institut Jules Bordet, Brussels

1200

RECRUITING

UCL Saint Luc, Brussels

2500

RECRUITING

Universitair Ziekenhuis Antwerpen (UZA), Edegem

2820

NOT_YET_RECRUITING

Imelda, Bonheiden

3000

RECRUITING

UZ Leuven Gasthuisberg, Leuven

3500

RECRUITING

Jessa Ziekenhuis, Hasselt

4000

RECRUITING

CHR Citadelle, Liège

RECRUITING

CHU Liège, Liège

5530

RECRUITING

CHU UCL Namur, Yvoir

6000

RECRUITING

Grand Hôpital de Charleroi, Charleroi

7000

RECRUITING

CHU Ambroise Paré, Mons

7301

RECRUITING

EpiCURA, Hornu

8500

RECRUITING

AZ Groeninge, Kortrijk

8800

RECRUITING

AZ Delta, Roeselare

9000

RECRUITING

Algemeen Ziekenhuis Maria Middelares (AZMM), Ghent

RECRUITING

Universitair Ziekenhuis Gent (UZ Gent), Ghent

9100

RECRUITING

Vitaz, Sint-Niklaas

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Janssen Pharmaceutica

INDUSTRY

lead

Universitaire Ziekenhuizen KU Leuven

OTHER